In addition, activation of the HGF‐MET pathway has been reported as a clinically relevant resistance mechanism in a variety of tumors, including trastuzumab resistance in HER2‐positive breast cancer, BRAF inhibitor resistance in melanoma, and bevacizumab resistance in glioblastoma.24, 25, 26. Here, ERBB2 is linked to melanoma.